Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in the Treatment of Lupus Nephritis: Prospective Real-world Study
ChiCTR2400091818Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in lupus nephritis (LN), sponsored by Peking University First Hospital. Primary endpoints: Systemic lupus erythematosus disease activity improves SRI-4, Complete renal remission and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
telitacicept
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on ChiCTR2400091818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091818.